Skip to main content
Seestargardt logo.

New lenses won’t clear up what Stargardt disease is obscuring

Stargardt disease type 1 (STGD1) causes irreversible retinal damage that standard visual acuity exams cannot diagnose.1,2 Yet, due to its low prevalence, it’s not always top of mind as a cause of vision loss.1

Unexplained central vision loss demands more than watch and wait1

How to diagnose

What is Stargardt disease?

Stargardt disease is a progressive inherited retinal disease (IRD) that results in irreversible central vision loss, often progressing to legal blindness (vision of 20/200 or worse).3-5 Stargardt disease is an autosomal recessive genetic condition and the most common form of juvenile macular degeneration.4,6 Although the classic presentation of Stargardt disease involves symptoms presenting in adolescence, clinical onset can occur anytime between childhood and the ninth decade of life.3,7

STGD1 impacts up to59,000 peoplein the US.8

Illustration showing toxic bisretinoids interacting with the ABCA4 protein in retinal cells.

Stargardt disease is caused by mutations of the ABCA4 gene6

ABCA4 is a transporter protein critical for recycling visual cycle byproducts. Learn more about how ABCA4 protein dysfunction can impact retinal health and vision.3

Watch the MOD video

Stargardt disease often starts with blurry vision3,9

The most common early symptoms include central vision that is blurry, distorted, or has dark areas. This vision loss cannot be corrected with lenses and often spares peripheral vision. Many patients begin to exhibit symptoms as early as childhood or adolescence, although symptom onset can occur later in adulthood.3,10,11

Other frequent symptoms include:

Dyschromatopsia
(impaired color discrimination)11
Photophobia
(sensitivity to bright light)4
Delayed dark adaptation
(slow adjustment to dim light)4

Unexplained vision loss may not be the only clue

Worsening vision often manifests as declining participation in sports and leisure activities, challenges with social engagement, or increased frustration with daily tasks. Many patients struggle with daily activities like driving and reading.9

Recognizing these symptoms as early as possible is critical to raise suspicion of Stargardt disease and take timely action toward a confirmed diagnosis.1

Nearly 60% of patients

struggle with social situations due to difficulty recognizing faces9*

“People would say hi to me, and I’d have no idea who they were.” — Person living with Stargardt disease

*In one study.

Early diagnosis of Stargardt disease is critical1

Patients often endure a lengthy diagnostic journey, as early symptoms can be challenging to identify due to the disease’s rarity and vast clinical variability.1

This prolonged delay means many patients experience irreversible vision loss before receiving a confirmed genetic diagnosis.1

An early Stargardt disease diagnosis ends clinical ambiguity and gives your patients the clarity they need to plan for their future.1

In one study, the diagnostic journey from symptom onset to evaluation by an IRD specialist averaged11 years1

Achieving a definitive diagnosis

Diagnosing Stargardt disease relies on advanced multimodal imaging and genetic testing.1,4

If you suspect Stargardt disease and lack advanced imaging capabilities. Consider immediately referring to a retina specialist to help confirm a diagnosis.1,4

When vision remains blurry, take action

Help prevent prolonged diagnostic journeys for your patients by referring them to a retina specialist for advanced imaging and genetic testing to confirm a diagnosis. This proactive step establishes a vital baseline for monitoring progression and prepares patients for emerging therapies.1,4

Diagnosing Stargardt disease

Understand the process
References:
  1. Li AS, Morales PC, Estrada-Puente C, Maldonado RS. Factors influencing the delayed diagnosis of Stargardt disease and impact on therapeutic opportunities. Retina. 2026;46(2):367-372. doi:10.1097/IAE.0000000000004691
  2. Lee W, Nõupuu K, Oll M, et al. The external limiting membrane in early-onset Stargardt disease. Invest Ophthalmol Vis Sci. 2014;55(10):6139-6149. doi:10.1167/iovs.14-15126
  3. Ghenciu LA, Hațegan OA, Stoicescu ER, Iacob R, Șışu AM. Emerging therapeutic approaches and genetic insights in Stargardt disease: a comprehensive review. Int J Mol Sci. 2024;25(16):8859. doi:10.3390/ijms25168859
  4. Dayma K, Rajanala K, Upadhyay A. Stargardt’s disease: molecular pathogenesis and current therapeutic landscape. Int J Mol Sci. 2025;26(14):7006. doi:10.3390/ijms26147006
  5. Polasek TM, Paneliya KJ, Lin T, et al. Effects of gastric acid suppression, Cytochrome P4503A inhibition and induction, and food on the pharmacokinetics of tinlarebant in healthy adults. Clin Pharmacol Drug Dev. 2026;15(1):e70009. doi:10.1002/cpdd.70009
  6. Aziz K, Swenor BK, Canner JK, Singh MS. The direct healthcare cost of Stargardt disease: a claims-based analysis. Ophthalmic Epidemiol. 2021;28(6):533-539. doi:10.1080/09286586.2021.1883675
  7. Runhart EH, Dhooge P, Meester-Smoor M, et al. Stargardt disease: monitoring incidence and diagnostic trends in the Netherlands using a nationwide disease registry. Acta Ophthalmol. 2022;100(4):395-402. doi:10.1111/aos.14996
  8. Mata NL, Weng S, Michaelides M, et al. Bisretinoids as a source of early photoreceptor pathology in Stargardt disease. Ophthalmic Res. 2025;68:555-572. doi:10.1159/000549368
  9. Roborel de Climens A, Tugaut B, Barbosa CD, Buggage R, Brun-Strang C. Living with Stargardt disease: insights from patients and their parents. Ophthalmic Genet. 2021;42(2):150-160. doi:10.1080/13816810.2020.1855663
  10. Stargardt disease: an overview for patients. Research to Prevent Blindness. Published 2026. Accessed September 9, 2026. https://www.rpbusa.org/eye-diseases/stargardt-disease/
  11. Tanna P, Strauss RW, Fujinami K, Michaelides M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2017;101(1):25-30. doi:10.1136/bjophthalmol-2016-308823